Literature DB >> 2970501

Persistence of specific antibodies after hepatitis B vaccination.

W Jilg1, M Schmidt, F Deinhardt.   

Abstract

Antibody levels to hepatitis B surface antigen (anti-HBs) in healthy adults vaccinated with three doses of plasma-derived hepatitis B vaccine, containing 20, 10 or 5 micrograms of antigen, were followed for 4-6 years. After vaccination, 1034 of 1076 individuals had developed anti-HBs and 1016 had antibody concentrations above 10 IU/l. 681 of all initial responders could be tested after 1 year, 520 after 2, 380 after 3 and 213 after 4 years. 72 and 39 individuals, respectively, of the 185 earliest vaccinated volunteers were available for retesting after 5 and 6 years. Four years after the first vaccination, anti-HBs levels in 34% had dropped below 10 IU/l. The persistence of anti-HBs above this value depended on the peak antibody response after the third vaccination. Whereas all vaccinees tested with peak anti-HBs levels above 10,000 IU/l still had levels above 10 IU/l after 6 years, no-one with initial values between 10 and 100 IU/l maintained antibody concentrations above 10 IU/l for longer than 4 years. The rate of decrease in anti-HBs was independent of the peak anti-HBs value, the vaccine dose, and the age and sex of the vaccinees.

Mesh:

Substances:

Year:  1988        PMID: 2970501     DOI: 10.1016/s0168-8278(88)80032-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Revised guidelines for booster vaccination against hepatitis B.

Authors:  D Holton
Journal:  CMAJ       Date:  1992-10-01       Impact factor: 8.262

Review 2.  Strategies for hepatitis B immunisation.

Authors:  A P Catterall; I M Murray-Lyon
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

3.  An assessment of the performance of self-reported vaccination status for hepatitis B, National Health and Nutrition Examination Survey 1999-2008.

Authors:  Maxine M Denniston; Kathy K Byrd; R Monina Klevens; Jan Drobeniuc; Saleem Kamili; Ruth B Jiles
Journal:  Am J Public Health       Date:  2013-08-15       Impact factor: 9.308

4.  Recommended childhood immunization schedule United States--1995. American Academy of Pediatrics and the Advisory Committee on Immunization Practices.

Authors:  J Gindler
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

5.  Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.

Authors:  Tino F Schwarz; Marek Spaczynski; Achim Schneider; Jacek Wysocki; Andrzej Galaj; Karin Schulze; Sylviane M Poncelet; Gregory Catteau; Florence Thomas; Dominique Descamps
Journal:  Hum Vaccin       Date:  2011-09-01

6.  Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults.

Authors:  Jing-jing Ren; Xue-wei Dai; Zheng-gang Jiang; Ling-zhi Shen; Yong-di Chen; Qian Li; Wen Ren; Ying Liu; Jun Yao; Lan-juan Li
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

7.  Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults.

Authors:  Jirí Beran; Lenka Hobzova; Veronika Wertzova; Sherine Kuriyakose; Maarten Leyssen; Murielle Surquin; Sophie Houard
Journal:  Hum Vaccin       Date:  2010-07-01

8.  Four-year experience with a recombinant hepatitis B vaccine.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

Review 9.  Update on diagnosis, management, and prevention of hepatitis B virus infection.

Authors:  F J Mahoney
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 10.  Traditional management of liver disorders.

Authors:  M Messner; P Brissot
Journal:  Drugs       Date:  1990       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.